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VARIABLE SURVIVAL DEATH TOTAL
Source of stem cell
Related BM/PBSC 32 10 37
Unrelated PBSC 10 12 22
Unrelated cord 4 4 8
HLA match
Matched 28 14 42
Haplo-identical 23 12 25
Conditioning
Regimen
Myelo-ablative 22 13 35
Non-myeloablative 19 13 32
Use of TBI 9 9 18
Underlying disease
Non-malignant 32 17 49
Malignant 9 9 18
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any HSCT Centre is good team work. We hope more such units are
developed with a similar public private partnership, so that no child in
need of HSCT is turned away for want of funds.
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Background: Regimen related toxicities form the major causes of trans-
plant related morbidity and mortality and have a major impact on the
outcome in children undergoing haematopoietic stem cell transplantation
(HSCT). Severe toxicity involving one organ or involvement of multiple
organs predicts a poor response. There is limited data from our country on
treatment outcomes of children undergoing HSCT requiring intensive care
support. In view of the high cost of supportive care, we aimed to analyse
the impact of aggressive paediatric intensive care unit (PICU) support in
these children.
Patients and methods: Data on all the PICU admissions among children
<18 years of age who underwent HSCT over 3 years from August 2013 to
August 2016 at Apollo Speciality hospital, Chennai was collected
by retrospective analysis of the hospital records including case ﬁles
and discharge or death summaries of patients. The risk factors analysed
wereTYPE OF DISEASE BENIGN VERSUS MALIGNANT
SOURCE OF GRAFT RELATED VERSUS UNRELATED
GRAFT VERSUS HOST
DISEASE - GVHD
PRESENT OR ABSENT
REASON FOR ADMISSION SEPSIS, CNS, GASTROINTESTINAL,
LIVER, RENAL, COAGULOPATHY
ĂResults: Of the total 238paediatric transplants during the studyduration, 72
children (30%) required PICU admission at a mean post infusion day of D+5.
About 30% of the children had been transplanted for malignancies and 70%
were benign with primary immune deﬁciency disorders requiring
maximumPICUcare. Sibling graftwasused in59% andunrelated graft in 41%
of children. One-third of children had acute GVHD at the time of admission.
The most common indication for PICU care was septic shock with 48% of
children. Seizures contributed to 22% and respiratory distress in 23.3%. Of
the children who had sepsis, the gastrointestinal tract was the focus in
29.7% and lungs in 43%. The incidence of various organ dysfunctions in our
cohort of patients included 73% hepatic involvement, 67% renal dysfunc-
tion, 56% gut involvement, 44% with coagulopathy and 43% CNS involve-
ment. When the mortality data was analysed, there was a trend towards
higher mortality in the PID group as these children had previously been
treated in intensive care units for various infections with multiple anti-
biotics. The mortality was higher in unrelated at 50% as compared to sib-
ling graft at 27%.The presence of graft versus host disease did not have an
effect on outcome. Sepsis with liver or renal dysfunction carried a high
mortality.
Conclusions: The overall mortality was 40% with bacterial sepsis with
septic shock and multi-organ dysfunction syndrome being the most
common cause of early transplant relatedmortality. The presence of one or
more organ dysfunction, especially hepatic or renal, was a predictor of
poor outcome. The mortality rates were higher in unrelated or mis-
matched grafts. However, about 60% of the children could be salvagedwith
PICU support and all children undergoing HSCT must be cared for in har-
mony with the PICU team.SCT-1_V1.7
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Aim: Haematopoietic stem cell transplantation (HSCT) is the only form of
cure in children with primary immune deﬁciency disorders (PID). There is
very little data to ﬁnd predictors of morbidity and mortality from our
country. We aimed to analyse information could translate into early
Abstracts / Pediatric Hematology Oncology Journal 1 (2016) S1eS33 S25intervention in order to improve outcome and survival for this rare group
of disorders.
Patients and methods: All children less than 18 years of age with PIDs
who were transplanted at Apollo Speciality Cancer hospital, Chennai from
2008 to 2016 were included in the study. Each of the PIDs were analyzed in
terms of the type of graft used, conditioning regimen, their rates of
engraftment, presence of co-morbidities at the time of HSCT, propensity
for GVHD and causes of mortality.
Results: A total of 62 PID transplants have been performed at our centre of
which 37 were T cell defects, 3 B cell defects, 11 Phagocytic defects, 10
primary Haemophagocytic Lymphohistiocytosis (HLH), 2 Mendelian sus-
ceptibility to Mycobacterial Disease (MSMD). Haploidentical HSCT was
offered in 13 children. The conditioning regimen was myeloablative in
children with Wiskott Aldrich Syndrome (WAS), Hyper IgM, and Chronic
Granulomatous Disease (CGD) with ﬂudarabine and buslphan. All children
with Severe Combined Immune Deﬁciency (SCID), Haemophagocytic
Lymphohistiocytosis (HLH), Common Variable Immune Deﬁciency (CVID),
Leucocyte Adhesion Defect (LAD) were treated with a reduced intensity
conditioning using ﬂudarabine and treosulphan. All haploidentical trans-
plantation were done based on the same reduced intensity protocol with
post transplant cyclophosphamide.
Co-morbidities at the time of HSCT namely infections, disseminated BCG
infection and failure to thrive was noted in 62.5% of the SCID babies. All
childrenwith WAS and Hyper IgM syndrome had eczema, bloody diarrhea
or pneumonia and refractory immune cytopenias. Children with CGD had
previous fungal granulomas or tuberculosis, hildren with CVID had bron-
chiectasis and children with LAD had non-healing ulcers.
Among children with SCID, most common cause of death was bacterial
sepsis whilst children with WAS died due to pulmonary haemorrhage
associated with immune cytopenias. Among those with HLH, 1 died of
immune haemolysis and the other 2 who were less than 6 months of age
died of pulmonary haemorrhage. Graft versus host disease (GVHD) was
the cause of death in 2 children and late cytomegaloviral (CMV) infection
resulted in death in 3 children. Primary graft failure was seen in 2 chil-
dren resulting in an overall survival rate among all children with PIDs
of 62%.
Conclusion: This is the ﬁrst series in India with survival rates of 62% in
children with Primary Immune Deﬁciency Disorders. Conditioning regi-
mens need to be chosen based on the genotype of an individual child. The
pre-engraftment phase is critical in babies with SCID due to maximum
mortality risk due to bacterial sepsis during this phase. Wiskott-Aldrich
syndrome poses unique challenges due to immune dysregulation and
these children need to be monitored for late immune cytopenias affecting
mortality in over 50%. GVHD is a predominant problem in children with
CGD with a risk of 80%. In children with primary HLH and less than 6
months of age, acute pulmonary haemorrhage is a risk factor affecting
mortality. In all these children, CMV viral load needs to be monitored and
treated early. Haploidentical HSCT is a feasible option in children with no
matched family donors with success rates on par with unrelated donor
HSCT.
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Objectives: Aim of the study is to analyze retrospectively the outcome of
allogenic hematopoeitic stem cell transplant (HSCT) for High Risk Acute
Pediatric Leukemia.
Methods: Retrospective data was analyzed for patient who underwent
allogenic HSCTat our center from January 2008 to June 2016. After a signed
informed consent a total of 42 transplants were done for 41 patients;
Median age was 16 years (range 3-21). The diagnosis was: acute
lymphoblastic leukemia in 26(63%) patients, acute myeloid leukemia
14(34%), and Acute Promyelocytic Leukemia in one. 33% were in ﬁrst
remission (CR1), 40% in second (CR2), and 27 % in third or with refractory
disease (CR3). Transplant type: MSD-30; Haploidentical HSCT-10& MUD-2. Conditioning regimen: Cy/TBI- 13; BU/Cy- 13; Flu/Mel- 4; Flu/Cy/TBI- 6;
Bu/ﬂu/Cy -3; In vitro T cell depletion and Flu/Mel/ATG/Thiotepa - 2 pa-
tients; Flu/AraC/Ida/Mel-1. Graft versus host disease (GVHD) prophylaxis
was Cyclosporine and Methotrexate in 31; PTCy with Tacrolimus/MMF in
9, and Tacrolimus/MMF in 2 patients.
Results: Out of 42 transplants, 5 patients received bone marrow, 37
patients received G- CSF mobilized peripheral blood stem cells. A me-
dian 7 million of CD34+ cells/kg was infused. A total of 39 transplants
(93%) engrafted. Median time for Neutrophil and platelet engraftment
was 11 days and 17 days respectively. Seven patient developed hemor-
rhagic cystitis. Acute graft GVHD (GR II e IV) was seen in 12(29%) and
chronic GVHD in 3 patients. CMV reactivation was seen in 5 patients and
was treated with Gancyclovir. Chimerism at day + 100 was available in
25(60%) cases; all of them had full donor hematopoiesis.Primary
rejection was seen in 2 patients and secondary rejection in 1 patient.
Fourteen patients (34%) have died, the causes were; relapse of leukemia
(n: 7), Infection (n: 4), GVHD (n: 3).Median follow up period was 250
days with overall survival (OS) for the whole group 66%. Discriminated
OS according to remission status was 71% in CR1, 70% in CR2 and 54% in
CR3.
Conclusion: Allogenic HSCT is a suitable option in pediatric high risk
leukemia and shows encouraging resultsSCT-1_V1.9
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Introduction: The major barriers to successful haplo-identical stem cell
transplantation (haplo-HSCT) in leukemia are disease relapse, graft
rejection and delayed immune recovery in settings of T-cell depletion and
acute GVHD in case of T-cell replete transplant. Leukemia relapse remains
one of the major causes of treatment failure. Graft manipulation with se-
lective removal of TCR a/b and CD 19 positive lymphocytes have been
developed to address these conundrums of haplo-HSCT.
Methods: We retrospectively reviewed clinical outcomes of haplo- HSCT
with TCR a/b and CD 19 depleted graft in pediatric patients with
leukemia.
Results: Eight patients (male n¼5; female n¼3) with a median age of 45
months (11 to 68) underwent 9 haplo-HSCT with TCR a/b and CD 19
depletion including a salvage transplantation (father donor in 7 and
mother in 1). Seven patients had relapsed acute lymphoid leukemia,
while one patient had relapsed acute myeloid leukemia. Myeloablative
conditioning regimens were used including Fludarabine-TBI-Etoposide,
Fludarabine-Busulphan-Melphalan and Fludarabine-ATG-TBI. Pre-
transplant rituximab was administered in 5 patients on day-1 to
decrease the risk of EBV associated PTLD. Stem cell source in all the
transplants was PBSC manipulated by TCR a/b and CD 19 depletion. Only
three received post-transplant GVHD prophylaxis. The graft contained a
median of 17.7106/kg (range 12.5 - 25.3) CD 34 cells, 0.04106/kg
(range 0.02 - 0.93) TCR a/b and 8.1106/kg (range 2.8 - 68.8) TCR g/
d cells. Primary neutrophil engraftment was achieved in all eight
transplantations and the median day of neutrophil engraftment was 12
days (range 9 - 20). Cumulative incidence of acute GVHD grade II-IV was
37.5% and of none of the patient developed grade III-IV acute GVHD.
Three patients developed CMV reactivation. One patient had secondary
graft failure on day +33 post transplantation and subsequently suc-
cumbed to infectious complications following a salvage transplant. One
patient with ALL had disease relapse, on day +236. Immune reconsti-
tution was robust with NK cells recovering the fastest (median of 213/uL
at day +21). With a median follow up of 472 days (range 153 - 635);
event free survival (EFS) was 75%.
Conclusion: Our data suggest that TCR a/b and CD 19 depletion for graft
manipulation in haplo-HSCT for acute leukemia results in good engraft-
ment, low rejection rates, low incidence of acute GVHD and, most strik-
ingly, low relapse rates.
